Is Sarepta Therapeutics Inc (SRPT) overvalued? · rev $1.90B
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
This page asks whether Sarepta Therapeutics Inc (SRPT) looks expensive on cached numbers — not a short thesis.
Latest reported SRPT revenue for 2024-12-31 was $1.90B. Net income was $235.2M. Revenue was up 53.0% from 2023-12-31 to 2024-12-31. SRPT currently screens at market cap $2.34B.
SRPT currently screens at market cap $2.34B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next SRPT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the SRPT stock page for the full model, not this heading.
Not investment advice.